Expression and prognostic value of matriptase in ovarian serous adenocarcinoma

Ji,Mei; Li,Shunshuang; Xie,Ya; Zhao,Zhao; Chang,Weizhong; Li,Yue; Cheng,Xinghan; Wang,Zhuo

doi:10.3892/ol.2017.5600

Expression and prognostic value of matriptase in ovarian serous adenocarcinoma

Authors:
- Mei Ji
- Shunshuang Li
- Ya Xie
- Zhao Zhao
- Weizhong Chang
- Yue Li
- Xinghan Cheng
- Zhuo Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 17, 2017 https://doi.org/10.3892/ol.2017.5600
Pages: 1741-1744

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that matriptase is involved in degradation of the extracellular matrix and angiogenesis, and is overexpressed in certain forms of epithelial cancer. The present study aimed to examine matriptase expression in ovarian serous adenocarcinoma, and to investigate its association with clinicopathological characteristics and patient prognosis. Matriptase expression was analyzed in 80 ovarian serous adenocarcinoma and 12 normal ovarian tissue samples by immunohistochemistry. All data were analyzed to evaluate the association between matriptase expression and clinicopathological parameters and overall survival. Immunohistochemistry demonstrated that matriptase protein was significantly overexpressed in the ovarian serous adenocarcinoma tissues compared with the normal ovarian tissues (P=0.0003). Furthermore, matriptase expression was significantly associated with clinical stage (P=0.0077) and lymph node metastasis (P=0.0111). Kaplan‑Meier survival curves demonstrated that patients with positive matriptase expression had significantly greater survival times (P=0.0008). Matriptase expression is associated with early stage and a greater survival time; therefore, this protein may function as a novel diagnostic and prognostic marker.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Uhland K: Matriptase and its putative role in cancer. Cell Mol Life Sci. 63:2968–2978. 2006. View Article : Google Scholar : PubMed/NCBI
4	Nakamura K, Hongo A, Kodama J, Abarzua F, Nasu Y, Kumon H and Hiramatsu Y: Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Res. 29:1685–1690. 2009.PubMed/NCBI
5	Tanimoto H, Underwood LJ, Wang Y, Shigemasa K, Parmley TH and O'Brien TJ: Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 22:104–114. 2001. View Article : Google Scholar : PubMed/NCBI
6	Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF and Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev. 15:217–227. 2006. View Article : Google Scholar : PubMed/NCBI
7	Vogel LK, Saebø M, Skjelbred CF, Abell K, Pedersen ED, Vogel U and Kure EH: The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer. 6:1762006. View Article : Google Scholar : PubMed/NCBI
8	Zeng L, Cao J and Zhang X: Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol. 11:6202–6207. 2005. View Article : Google Scholar : PubMed/NCBI
9	Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF and Lin YF: Expression of serine protease matriptase in renal cell carcinoma: Correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol. 14:65–72. 2006. View Article : Google Scholar : PubMed/NCBI
10	Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Anfossi S, Roman JJ, O'Brien T and Pecorelli S: The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer. 98:1898–1904. 2003. View Article : Google Scholar : PubMed/NCBI
11	Nakamura K, Hongo A, Kodama J, Abarzua F, Nasu Y, Kumon H and Hiramatsu Y: Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Res. 29:1685–1690. 2009.PubMed/NCBI
12	List K, Bugge TH and Szabo R: Matriptase: Potent proteolysis on the cell surface. Mol Med. 12:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
13	Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR and Anton-Culver H: Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J Am Coll Surg. 220:940–950. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zeppernick F and Meinhold-Heerlein L: The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014. View Article : Google Scholar : PubMed/NCBI
15	Chang C and Werb Z: The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11:S37–S43. 2001. View Article : Google Scholar : PubMed/NCBI
16	Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L and Chiarugi V: Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis. 19:193–207. 2002. View Article : Google Scholar : PubMed/NCBI
17	Lisk K, Bugge TH and Szabo R: Matriptase: Potent proteolysis on the cell surface. Mol Med. 12:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
18	Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR and Craik CS: Cellular localization of membrane-type serine protease1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem. 275:26333–26342. 2000. View Article : Google Scholar : PubMed/NCBI
19	Lee SL, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem. 275:36720–36725. 2000. View Article : Google Scholar : PubMed/NCBI
20	Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H and Sellar GC: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res. 8:1101–1107. 2002.PubMed/NCBI